ArticlePharmaceutical medicine2026
The Evolution of Medical Affairs Central Teams: Shaping Strategic Action and Driving Healthcare Transformation Through Scientific Interaction.
Article in Pharmaceutical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Compliance to Strategic Partner: The Transformation of Regulatory Affairs in AstraZeneca Local Affiliates.Pharmaceutical medicine · 2026Article
- Benchmark Survey on Content Development and Key Performance Indicators: A phactMI Benchmarking Survey Update.Therapeutic innovation & regulatory science · 2026Article
- Transformation of a Medical Information Department to Meet the New Healthcare Realities of the Post-Pandemic Era.Pharmaceutical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolving role of Medical Affairs (MA) has positioned this department as a key element in the development and lifecycle management of pharmaceutical products. In response to internal and external assessments, AstraZeneca (AZ) Spain implemented a transformation of its MA central teams through a newly designed Working Model. This model ensures full engagement across the product lifecycle, spanning early access, pre-launch, launch, and post-launch, balancing global strategy with local execution, enhancing cross-functional collaboration, and timely evidence generation. Central to this transformation is the deployment of four coordinated teams: the Early Asset Strategy Team, the Launch Readiness Team, the Core Value Team, and the Brand Team. These teams follow a structured work methodology and coordination model underpinned by dedicated information management processes that streamline communication and knowledge transfer. Training and capability-building programmes were also introduced to strengthen critical functional and leadership competencies. These changes aim to improve product positioning, accelerate market access, and drive value-based healthcare outcomes. The initiative aligns with broader industry trends emphasising early stakeholder engagement, data integration, and patient-centric strategies. By fostering agility, strategic foresight, and internal consistency, the transformation of MA central teams at AZ Spain provides a replicable model for enhancing MA's contribution to product development and healthcare ecosystem innovation. This article builds on our previous publications about the national ecosystem assessment of stakeholder needs, the definition of our MA transformation framework (articulating the strategic roadmap), and the description of the evolution of in-field MA teams in AZ Spain. Here we detail the transformation of the MA central teams and their working model. Future MA evolution will integrate emerging technologies like artificial intelligence (AI) and digital tools, improving stakeholder engagement, evidence generation, and decision making. The transformative potential of AI in anticipating trends and optimising trials will enhance the role of MA in driving innovation and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.